why is host-targeted better?

Host-targeting is a unique property of a therapeutic that bolsters the ability of the ‘host’ — the person at risk for a disease — to resist an infection or disease. Most of today’s infectious disease treatments are molecules targeted at specific pathogens, an approach that can foster the emergence of drug resistance and limit the further utility of the drug. A novel therapeutic approach like iCALM offers significant advantages for improved outcomes, reduces patient treatment burdens, and lowers health care costs. These distinct iCALM advantages result from its capacity to engage the airway’s own robust host defenses, enhance infection-fighting capabilities and reduce inflammation in advance of or early in the disease process against a wide array of respiratory pathogens and insults.